| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
20,256 |
19,433 |
$1.20M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
10,569 |
10,265 |
$621K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,890 |
1,752 |
$116K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,005 |
931 |
$63K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
908 |
829 |
$43K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
363 |
343 |
$23K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
937 |
878 |
$11K |
| 99201 |
|
242 |
229 |
$11K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,451 |
2,316 |
$6K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,049 |
978 |
$3K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
983 |
699 |
$2K |
| 81025 |
|
475 |
417 |
$1K |
| 81002 |
|
854 |
830 |
$1K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
225 |
213 |
$921.25 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
163 |
158 |
$643.40 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
39 |
38 |
$364.76 |
| 81003 |
|
269 |
241 |
$341.14 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
84 |
71 |
$285.51 |
| 87400 |
|
13 |
13 |
$70.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
55 |
52 |
$59.81 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
16 |
13 |
$19.21 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
29 |
27 |
$3.04 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
28 |
27 |
$1.80 |
| 99000 |
|
4,454 |
4,357 |
$1.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
73 |
66 |
$0.25 |